Treatment of acute and chronic congestive heart failure by vasodilator-afterload reduction.
D000208:Acute Disease; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects; D002302:Cardiac Output / Q000187:drug effects; D002908:Chronic Disease; D003971:Diastole; D006333:Heart Failure / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D006830:Hydralazine / Q000627:therapeutic use; D009131:Muscle, Smooth, Vascular; D009599:Nitroprusside / Q000627:therapeutic use; D010646:Phentolamine / Q000627:therapeutic use; D011224:Prazosin / Q000627:therapeutic use; D011942:Receptors, Adrenergic, alpha / Q000187:drug effects; D011943:Receptors, Adrenergic, beta / Q000187:drug effects; D014665:Vasodilator Agents / Q000627:therapeutic use*; D014690:Venous Pressure / Q000187:drug effects
D000959:Antihypertensive Agents; D011942:Receptors, Adrenergic, alpha; D011943:Receptors, Adrenergic, beta; D014665:Vasodilator Agents; D009599:Nitroprusside; D006830:Hydralazine; D011224:Prazosin; D010646:Phentolamine